Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Mai 2019 16:03 ET | Quelle: CohBar, Inc.

CohBar Reports First Quarter 2019 Financial Results and Business Update

MENLO PARK, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
07. Mai 2019 09:00 ET | Quelle: CohBar, Inc.

CohBar Appoints Steven B. Engle as Chief Executive Officer

MENLO PARK, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
03. Mai 2019 09:00 ET | Quelle: CohBar, Inc.

CohBar to Resume its Phase 1a/1b Clinical Trial

MENLO PARK, Calif., May 03, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
26. April 2019 15:35 ET | Quelle: CohBar, Inc.

CohBar to Announce 2019 First Quarter Financial Results and Provide Business Update on May 7, 2019

MENLO PARK, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
23. April 2019 09:00 ET | Quelle: CohBar, Inc.

CohBar Announces Key Opinion Leader Conference Call and Webcast

Call to feature thought leaders discussing mitochondria and mitochondrial-drived peptides as a potential source of novel therapeutics Call and webcast scheduled for May 2, 2019; 10:30-11:45am EDT...
22. April 2019 09:00 ET | Quelle: CohBar, Inc.

CohBar Announces the Appointment of David Greenwood to its Board of Directors

MENLO PARK, Calif., April 22, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
18. März 2019 16:03 ET | Quelle: CohBar, Inc.

CohBar Reports Fourth Quarter 2018 Financial Results and Provides Business Update

MENLO PARK, Calif., March 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
04. März 2019 09:00 ET | Quelle: CohBar, Inc.

CohBar to Announce 2018 Fourth Quarter Financial Results and Host Conference Call on March 18, 2019

MENLO PARK, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
11. Februar 2019 09:00 ET | Quelle: CohBar, Inc.

CohBar Announces the Appointment of Dr. Phyllis Gardner to its Board of Directors

MENLO PARK, Calif., Feb. 11, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...
10. Dezember 2018 16:05 ET | Quelle: CohBar, Inc.

CohBar Appoints Philippe P. Calais, Pharm.D., Ph.D. as Interim Chief Executive Officer

MENLO PARK, Calif., Dec. 10, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...

Vorherige Seite